Methylmalondialdehyde (MDA) is a reactive aldehyde and a product of lipid peroxidation. It is formed when polyunsaturated fatty acids are oxidized, which can occur under conditions of oxidative stress. MDA is a marker of oxidative damage and has been implicated in various diseases, including cardiovascular disease, cancer, and neurodegenerative disorders. It is studied to understand the role of oxidative stress in these diseases and to develop potential therapeutic strategies to reduce oxidative damage. MDA is also used as a biomarker for measuring oxidative stress in biological systems.'
methylmalondialdehyde: structure given in first source
ID Source | ID |
---|---|
PubMed CID | 98735 |
MeSH ID | M0103446 |
Synonym |
---|
methylmalondialdehyde |
nsc-162796 |
16002-19-0 |
nsc162796 |
2-methylpropanedial |
propanedial, methyl- |
propanedial, 2-methyl- |
unii-n9y140nwk2 |
nsc 162796 |
n9y140nwk2 , |
methylmalonaldehyde |
VXYSFSCCSQAYJV-UHFFFAOYSA-N |
DTXSID50166786 |
FT-0717122 |
2-methylmalonaldehyde |
malonaldehyde, methyl- |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (37.50) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (62.50) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.94) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |